At present, two powerful PROTAC candidates have entered phase 1/2 clinical trials developed by the Arvinas company, namely, ARV-110 targeting androgen receptors (AR) for treating prostate cancer (79), and ARV-471 targeting estrogen receptors (ER) for treating breast cancer (80). This evidence concerns the gene ESR1 and prostate carcinoma.